Cargando…

The Effect of Rivastigmine Transdermal Patch on Sleep Apnea in Patients with Probable Alzheimer's Disease

BACKGROUND AND PURPOSE: This study was designed to evaluate the effect on sleep of rivastigmine transdermal patch in patients with probable Alzheimer's disease (AD). METHODS: Patients with probable AD underwent a sleep questionnaire, overnight polysomnography and neuropsychological tests before...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Hyeyun, Han, Hyun Jeong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Dementia Association 2016
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6428022/ https://www.ncbi.nlm.nih.gov/pubmed/30906358 http://dx.doi.org/10.12779/dnd.2016.15.4.153

Ejemplares similares

Efficacy and Safety of Switching from Oral Cholinesterase Inhibitors to the Rivastigmine Transdermal Patch in Patients with Probable Alzheimer's Disease
por: Han, Hyun Jeong, et al.
Publicado: (2011)

An Atypical Cutaneous Reaction to Rivastigmine Transdermal Patch
por: Grieco, T., et al.
Publicado: (2011)

Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer’s disease: a review
por: Kurz, A, et al.
Publicado: (2009)

Characteristics of patients with Alzheimer’s disease who switch to rivastigmine transdermal patches in routine clinical practice
por: López-Pousa, Secundino, et al.
Publicado: (2013)

Preparation and Characterization of Rivastigmine Transdermal Patch Based on Chitosan Microparticles
por: Sadeghi, Mohsen, et al.
Publicado: (2016)

Once-daily transdermal rivastigmine in the treatment of Alzheimer’s disease
por: Wentrup, Andreas, et al.
Publicado: (2009)

Influence of Rivastigmine transdermal on butyrylcholinesterase levels in patients with Alzheimer's disease
por: dos Santos, Gustavo Alves Andrade, et al.
Publicado: (2011)

Third degree atrioventricular block associated with treatment with rivastigmine transdermal patch
por: Knudtzen, Fredrikke C., et al.
Publicado: (2013)

Effectiveness and tolerability of transdermal rivastigmine in the treatment of Alzheimer’s disease in daily practice
por: Seibert, Johannes, et al.
Publicado: (2012)

A prospective study on the use of rivastigmine transdermal patch in Alzheimer’s dementia in a routine clinical setting
por: Nazir, Ejaz, et al.
Publicado: (2010)

A prospective non-interventional study for evaluation of quality of life in patients with Alzheimer’s disease treated with rivastigmine transdermal patch
por: Vagenas, Vassileios, et al.
Publicado: (2015)

Efficacy of rivastigmine transdermal therapy on low food intake in patients with Alzheimer's disease: The Attitude Towards Food Consumption in Alzheimer's Disease Patients Revive with Rivastigmine Effects study
por: Tsuno, Norifumi, et al.
Publicado: (2019)

Comparison of the effects of transdermal and oral rivastigmine on cognitive function and EEG markers in patients with Alzheimer’s disease
por: Moretti, Davide V., et al.
Publicado: (2014)

The Effect of Vascular Risk Factors on the Efficacy of Rivastigmine Patch and Capsule Treatment in Alzheimer's Disease
por: Farlow, M.R., et al.
Publicado: (2011)

Effects of a Rivastigmine Patch on Self-Care Activities in Patients with Alzheimer's Disease plus Cerebrovascular Disease
por: Kim, Yong Kyun, et al.
Publicado: (2014)

Rivastigmine in the treatment of patients with Alzheimer’s disease
por: Müller, Thomas
Publicado: (2007)

The transdermal formulation of rivastigmine improves caregiver burden and treatment adherence of patients with Alzheimer's disease under daily practice conditions
por: Adler, G, et al.
Publicado: (2014)

Comparative Bioavailability Study of a Novel Multi-Day Patch Formulation of Rivastigmine (Twice Weekly) with Exelon(®) Transdermal Patch (Daily)- A Randomized Clinical Trial
por: Schurad, Bjoern, et al.
Publicado: (2022)

Rivastigmine in the treatment of Alzheimer’s disease: an update
por: Onor, Maria Luisa, et al.
Publicado: (2007)

The Efficacy of Transdermal Rivastigmine in Mild to Moderate Alzheimer’s Disease with Concomitant Small Vessel Cerebrovascular Disease: Findings from an Open-Label Study
por: Yatawara, Chathuri, et al.
Publicado: (2021)

Transdermal rivastigmine for HIV-associated cognitive impairment: A randomized pilot study
por: Muñoz-Moreno, Jose A., et al.
Publicado: (2017)

Polymeric Microneedles for Transdermal Delivery of Rivastigmine: Design and Application in Skin Mimetic Model
por: Guimarães, Tânia M. T., et al.
Publicado: (2022)

Rotigotine transdermal patch and sleep in Parkinson’s disease: where are we now?
por: Rosa-Grilo, Miguel, et al.
Publicado: (2017)

Rivastigmine in Alzheimer’s disease: Cognitive function and quality of life
por: Annicchiarico, Roberta, et al.
Publicado: (2007)

Efficacy, Safety, and Tolerability of Switching from Oral Cholinesterase Inhibitors to Rivastigmine Transdermal Patch with 1-Step Titration in Patients with Mild to Moderate Alzheimer's Disease: A 24-Week, Open-Label, Multicenter Study in Japan
por: Ueda, Kengo, et al.
Publicado: (2019)

Adverse drug events affecting medication persistence with rivastigmine patch application
por: Osada, Takashi, et al.
Publicado: (2018)

Effects of Renal Impairment on Steady-State Plasma Concentrations of Rivastigmine: A Population Pharmacokinetic Analysis of Capsule and Patch Formulations in Patients with Alzheimer’s Disease
por: Lefèvre, Gilbert, et al.
Publicado: (2016)

Domperidone effective in preventing rivastigmine-related gastrointestinal disturbances in patients with Alzheimer’s disease
por: Kano, Osamu, et al.
Publicado: (2013)

At-home wireless sleep monitoring patches for the clinical assessment of sleep quality and sleep apnea
por: Kwon, Shinjae, et al.
Publicado: (2023)

Improper Application of a Rivastigmine Patch to the Back of the Neck Induced Toxic Symptoms
por: Matsuzono, Kosuke, et al.
Publicado: (2023)

A 24-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of the Rivastigmine Patch in Japanese Patients with Alzheimer's Disease
por: Nakamura, Yu, et al.
Publicado: (2011)

Rivastigmine improves dual-task gait velocity in patients with Alzheimer’s disease
por: Shimura, Hideki, et al.
Publicado: (2021)

Transdermal iontophoresis patch with reverse electrodialysis
por: Lee, Joon, et al.
Publicado: (2017)

Potential therapeutic effect of nanobased formulation of rivastigmine on rat model of Alzheimer’s disease
por: Ismail, Manal Fouad, et al.
Publicado: (2013)

Effects of Rivastigmine on Brain Functional Networks in Patients With Alzheimer Disease Based on the Graph Theory
por: Zhang, Jiangtao, et al.
Publicado: (2021)

Rivastigmine modifies the α-secretase pathway and potentially early Alzheimer’s disease
por: Ray, Balmiki, et al.
Publicado: (2020)

Comparative study of rivastigmine and galantamine on the transgenic Drosophila model of Alzheimer's disease
por: Siddique, Yasir Hasan, et al.
Publicado: (2022)

Effectiveness of the 10 cm(2) Rivastigmine Patch in Taiwanese Patients with Mild-to-Moderate Alzheimer’s Dementia: A 48-Week Real-World Observational Study
por: Chang, Chiung-Chih, et al.
Publicado: (2021)

Formulation optimization of galantamine hydrobromide loaded gel drug reservoirs in transdermal patch for Alzheimer’s disease
por: Woo, Fong Yen, et al.
Publicado: (2015)

Formulation and Evaluation of Transdermal Patch of Repaglinide
por: Prajapati, Shailesh T., et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_l6fns8svj1jpi4nfmnsft5r7ar